The Efficacy and Safety of Albumin-bound Paclitaxel Plus Carboplatin As Neoadjuvant Therapy for Potentially Resectable Lung Squamous Cell Carcinoma: a Real-world Retrospective Cohort Study

Overview

Journal Transl Lung Cancer Res

Date 2022 May 9

PMID 35529791

Authors

Wenjuan Jiang

Yuling Zhou

Liang Zeng

Yi Xiong

Li Liu

Chunhua Zhou

Haiyan Yang

Hui Guo

Fabrizio Minervini

Stefano Bongiolatti

Nong Yang

Yongchang Zhang

Min Tao

Affiliations

Soon will be listed here.

Abstract

Background: In early and locally advanced stage non-small-cell lung cancer (NSCLC), surgery is the cornerstone of curative-intent treatments. And the addition of neoadjuvant or adjuvant chemotherapy can prolong overall survival (OS), albumin-bound paclitaxel plus carboplatin (ab-PC) as neoadjuvant therapy (NAT) has showed favorable effect for resectable lung squamous cell carcinoma (LSCC) with IIIA. However, to date, no study has investigated the efficacy of ab-PC as neoadjuvant chemotherapy in potentially resectable LSCC with IIIA-IIIB. This study aimed to evaluate the efficacy and safety of the regimen in potentially resectable LSCC.

Methods: Enrolled patients with stage IIIA and IIIB potentially resectable LSCC treated with neoadjuvant albumin-bound paclitaxel (nab-P; 100 mg/m, days 1, 8, and 15) and carboplatin (6 mg/mL/min, day 1) for two 21-day cycles at the Hunan Cancer Hospital between December 2017 and December 2019. The primary endpoint was the surgery conversion rate (SCR). Secondary endpoints included objective response rate (ORR), margin-free (R0) resection, major pathological response (mPR), and safety.

Results: In total, 49 patients were included in the study, with an overall response rate (ORR) of 67% (33/49). The SCR was 67% (33/49). Only 31 patients underwent surgery eventually, and R0 resection was achieved in 30 patients. Further, 4 (13%) and 11 (35%) of the 31 patients had a pathological complete response (pCR) and mPR, respectively. In total, 23 patients experienced treatment-related adverse events (TRAEs). The most common TRAE was liver disfunction (9 patients, 18%). Only 1 patient (2%) experienced a grade ≥3 TRAE of leukopenia. There were no treatment-related deaths or treatment discontinuations.

Conclusions: In this study, we found a high SCR (67%) and mPR (35%) after ab-PC treatment for stage IIIA and IIIB potentially resectable LSCC. ab-PC maybe considered a neoadjuvant chemotherapy option for potentially resectable LSCC patients.

Citing Articles

Squamous cell carcinoma of the cystic duct: A case report and literature review.

Wang H, Lu J, Hao L, Li H, Li N, Zheng W Medicine (Baltimore). 2023; 102(41):e35430.

PMID: 37832089 PMC: 10578676. DOI: 10.1097/MD.0000000000035430.

Genes whose expressions in the primary lung squamous cell carcinoma are able to accurately predict the progression of metastasis through lymphatic system, inferred from a bioinformatics analyses.

Khashei Varnamkhasti K, Moghanibashi M, Naeimi S Sci Rep. 2023; 13(1):6733.

PMID: 37185598 PMC: 10130036. DOI: 10.1038/s41598-023-33897-3.

References

Martinez P, Peters S, Stammers T, Soria J . Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2019; 25(9):2691-2698. DOI: 10.1158/1078-0432.CCR-18-3904. View

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

Felip E, Rosell R, Maestre J, Rodriguez-Paniagua J, Moran T, Astudillo J . Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010; 28(19):3138-45. DOI: 10.1200/JCO.2009.27.6204. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Chen Z, Fillmore C, Hammerman P, Kim C, Wong K . Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014; 14(8):535-46. PMC: 5712844. DOI: 10.1038/nrc3775. View

Reuss J, Anagnostou V, Cottrell T, Smith K, Verde F, Zahurak M . Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020; 8(2). PMC: 7488786. DOI: 10.1136/jitc-2020-001282. View

. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014; 383(9928):1561-71. PMC: 4022989. DOI: 10.1016/S0140-6736(13)62159-5. View

Cottrell T, Thompson E, Forde P, Stein J, Duffield A, Anagnostou V . Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol. 2018; 29(8):1853-1860. PMC: 6096736. DOI: 10.1093/annonc/mdy218. View

Qu Y, Emoto K, Eguchi T, Aly R, Zheng H, Chaft J . Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. J Thorac Oncol. 2018; 14(3):482-493. PMC: 6382593. DOI: 10.1016/j.jtho.2018.11.017. View

10.

West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter H . Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase.... Lancet Oncol. 2019; 20(7):924-937. DOI: 10.1016/S1470-2045(19)30167-6. View

11.

Pignon J, Tribodet H, Scagliotti G, Douillard J, Shepherd F, Stephens R . Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26(21):3552-9. DOI: 10.1200/JCO.2007.13.9030. View

12.

Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher D . Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol. 2009; 10(8):785-93. DOI: 10.1016/S1470-2045(09)70172-X. View

13.

Shu C, Gainor J, Awad M, Chiuzan C, Grigg C, Pabani A . Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020; 21(6):786-795. DOI: 10.1016/S1470-2045(20)30140-6. View

14.

Zhou C, Wu Y, Chen G, Liu X, Zhu Y, Lu S . BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33(19):2197-204. DOI: 10.1200/JCO.2014.59.4424. View

15.

Gandara D, Hammerman P, Sos M, Lara Jr P, Hirsch F . Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res. 2015; 21(10):2236-43. PMC: 4862209. DOI: 10.1158/1078-0432.CCR-14-3039. View

16.

Arbour K, Riely G . Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review. JAMA. 2019; 322(8):764-774. DOI: 10.1001/jama.2019.11058. View

17.

Gridelli C, Chen T, Ko A, OBrien M, Ong T, Socinski M . nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial. Drug Des Devel Ther. 2018; 12:1445-1451. PMC: 5973475. DOI: 10.2147/DDDT.S155750. View

18.

Osmani L, Askin F, Gabrielson E, Li Q . Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2017; 52(Pt 1):103-109. PMC: 5970946. DOI: 10.1016/j.semcancer.2017.11.019. View

19.

Bryan D, Donington J . The Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer. Curr Treat Options Oncol. 2019; 20(4):27. DOI: 10.1007/s11864-019-0624-7. View

20.

Forde P, Chaft J, Smith K, Anagnostou V, Cottrell T, Hellmann M . Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018; 378(21):1976-1986. PMC: 6223617. DOI: 10.1056/NEJMoa1716078. View